These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25848292)

  • 1. Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study.
    Shammas NW; Shammas GA; Keyes K; Duske S; Kelly R; Jerin M
    Ther Clin Risk Manag; 2015; 11():469-74. PubMed ID: 25848292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
    Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
    Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
    Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
    J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis: The MARINA Randomized, Double-Blinded, Controlled Pilot Trial.
    Koh JS; Hung OY; Eshtehardi P; Kumar A; Rabah R; Raad M; Kumar S; Chaudhry S; Gupta S; Hosseini H; Brilakis E; Corban M; Sabbak N; Burnett GM; Liu C; Mehta PK; Quyyumi AA; Samady H
    Circ Cardiovasc Interv; 2020 Dec; 13(12):e008204. PubMed ID: 33272036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
    Bairey Merz CN; Handberg EM; Shufelt CL; Mehta PK; Minissian MB; Wei J; Thomson LE; Berman DS; Shaw LJ; Petersen JW; Brown GH; Anderson RD; Shuster JJ; Cook-Wiens G; Rogatko A; Pepine CJ
    Eur Heart J; 2016 May; 37(19):1504-13. PubMed ID: 26614823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
    Arnold SV; Morrow DA; Wang K; Lei Y; Mahoney EM; Scirica BM; Braunwald E; Cohen DJ;
    Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):107-15. PubMed ID: 20031797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Ranolazine in Patients with Chest Pain and Normal Coronaries- A Hospital Based Study.
    Saha S; Ete T; Kapoor M; Jha PK; Megeji RD; Kavi G; Warjri SB; Mishra A
    J Clin Diagn Res; 2017 Apr; 11(4):OC14-OC16. PubMed ID: 28571183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U; Ezekowitz M; Fenney L; Chiang YK
    Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study).
    Bavry AA; Park KE; Choi CY; Mahmoud AN; Wen X; Elgendy IY
    Cardiol Ther; 2017 Jun; 6(1):81-88. PubMed ID: 28044265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial.
    Mehta PK; Sharma S; Minissian M; Harsch MR; Martinson M; Nyman JA; Shaw LJ; Bairey Merz CN; Wenger NK
    J Womens Health (Larchmt); 2019 May; 28(5):573-582. PubMed ID: 30888919
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical experience with ranolazine in a veteran population with chronic stable angina.
    Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
    Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
    Fanaroff AC; James SK; Weisz G; Prather K; Anstrom KJ; Mark DB; Ben-Yehuda O; Alexander KP; Stone GW; Ohman EM
    J Am Coll Cardiol; 2017 May; 69(18):2304-2313. PubMed ID: 28473136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.
    Villano A; Di Franco A; Nerla R; Sestito A; Tarzia P; Lamendola P; Di Monaco A; Sarullo FM; Lanza GA; Crea F
    Am J Cardiol; 2013 Jul; 112(1):8-13. PubMed ID: 23558043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial.
    Weisz G; Farzaneh-Far R; Ben-Yehuda O; Debruyne B; Montalescot G; Lerman A; Mahmud E; Alexander KP; Ohman EM; White HD; Olmsted A; Walker GA; Stone GW
    Am Heart J; 2013 Dec; 166(6):953-959.e3. PubMed ID: 24268208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranolazine and Microvascular Angina by PET in the Emergency Department: Results From a Pilot Randomized Controlled Trial.
    Safdar B; D'Onofrio G; Dziura J; Russell RR; Johnson C; Sinusas AJ
    Clin Ther; 2017 Jan; 39(1):55-63. PubMed ID: 28081848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.
    Arnold SV; McGuire DK; Spertus JA; Li Y; Yue P; Ben-Yehuda O; Belardinelli L; Jones PG; Olmsted A; Chaitman BR; Kosiborod M
    Am Heart J; 2014 Oct; 168(4):457-465.e2. PubMed ID: 25262254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study.
    Ahmed B; Mondragon J; Sheldon M; Clegg S
    Cardiovasc Revasc Med; 2017 Sep; 18(6):431-435. PubMed ID: 28576663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial.
    Birkeland K; Khandwalla RM; Kedan I; Shufelt CL; Mehta PK; Minissian MB; Wei J; Handberg EM; Thomson LE; Berman DS; Petersen JW; Anderson RD; Cook-Wiens G; Pepine CJ; Bairey Merz CN
    JMIR Res Protoc; 2017 Dec; 6(12):e255. PubMed ID: 29263019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.